Our portfolio
Vascuros Medical
As an international medical device startup, Vascuros medical focuses on developing innovative minimally invasive interventional devices with high clinical value to solve the challenges faced by vascular diseases.
Headquartered in Singapore, jMedtech Pte Ltd established Vascuros Medical in Shanghai Zhangjiang high-tech industrial park in 2015. The new generation of medicine balloon can be used to treat peripheral vascular stenosis, cardiac vascular stenosis, hemodialysis access stenosis and other vascular diseases. The new micro-nano coating technology is used to insert the drug particles into the coating surface. The new catheter and balloon design allows the drug to be released as soon as it reaches the lesion site, resulting in a near-zero drug loss rate. Vascuros capsules deliver precise, controlled dosing and efficient, uniform and long-lasting drug absorption. It can be used to improve the therapeutic effect and safety of supracapsular vascular stenosis. It is also improving the efficacy and safety of stent restenosis; addressing subgenual vascular stenosis and narrowing of small blood vessels in the heart. Clinical trials have begun at Beijing Fuwai hospital.
Founder Dr Luo Jing Nan is a Doctorate of Biomaterials from National University of Singapore. He is the "expert of the China National Thousand Talents plan". He has founded two companies previously, one is jMedtech Coating Technologies, which was acquired by Shanghai Microhurt, and another is Orchid Medical, which was acquired by silicon valley incubator The Foundry.
Chuang Capital participated in the series A investment.
Headquartered in Singapore, jMedtech Pte Ltd established Vascuros Medical in Shanghai Zhangjiang high-tech industrial park in 2015. The new generation of medicine balloon can be used to treat peripheral vascular stenosis, cardiac vascular stenosis, hemodialysis access stenosis and other vascular diseases. The new micro-nano coating technology is used to insert the drug particles into the coating surface. The new catheter and balloon design allows the drug to be released as soon as it reaches the lesion site, resulting in a near-zero drug loss rate. Vascuros capsules deliver precise, controlled dosing and efficient, uniform and long-lasting drug absorption. It can be used to improve the therapeutic effect and safety of supracapsular vascular stenosis. It is also improving the efficacy and safety of stent restenosis; addressing subgenual vascular stenosis and narrowing of small blood vessels in the heart. Clinical trials have begun at Beijing Fuwai hospital.
Founder Dr Luo Jing Nan is a Doctorate of Biomaterials from National University of Singapore. He is the "expert of the China National Thousand Talents plan". He has founded two companies previously, one is jMedtech Coating Technologies, which was acquired by Shanghai Microhurt, and another is Orchid Medical, which was acquired by silicon valley incubator The Foundry.
Chuang Capital participated in the series A investment.
Accunome Sciences
Accunome Sciences is a San diego-based company that develops a fully automated molecular diagnostic platform based on fluorescence quantitative PCR, and a digital PCR, reagent and application platform. According to relevant statistics, the market capacity of molecular diagnosis in 2016 was 6 billion US dollars, and it is expected that the market capacity will exceed 10.2 billion US dollars in 2021.
Accunome has developed a stable medium to high throughout molecular diagnostic platform, from sample to result. The platform allows each batch to mix different samples and test targets, in fully automated manner to improve test performance and consistency. Accunome uses pure physical segmentation to experiment with digital reactions and is suitable for any PCR system on the market.
The founder, Yang Xing, holds a PhD in electrical engineering from California Institute of Technology and has more than 20 years of experience in IVD and life sciences. He is a member of BayHelix and a former director of SABPA (San Diego).
Chuang Capital participated in the series A investment in 2018. In March 2020, Accunome announced the completion of Series A + financing. This round was led by Zhen Fund, and Chuang Capital continued to follow in this round.
EndoMaster
Chuang Capital's portfolio company, medical robotics startup EndoMaster has raised S$20.5 million in Series B funding, said to be one of the largest such amounts for a medical technology (medtech) company in Singapore. Chuang Capital not only joined as a co-investor in this round, it also provided EndoMaster with financial advisory services, which successfully resulted in other prominent investors from China to join this round.